Open AccessIndian society for study of pain, cancer pain special interest group guidelines on pharmacological management of cancer pain (Part I)
Author(s) -
RaghuS Thota,
Raghavendra Ramanjulu,
Arif Ahmed,
Pranay Jain,
Naveen Salins,
Sushma Bhatnagar,
Aparna Chatterjee,
Dipasri Bhattacharya
Publication year - 2020
Publication title -
indian journal of palliative care/indian journal of palliative care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 26
eISSN - 1998-3735
pISSN - 0973-1075
DOI - 10.4103/0973-1075.285692
Subject(s) - medicine , cancer pain , codeine , palliative care , pain ladder , analgesic , tramadol , cancer , quality of life (healthcare) , opioid , pain management , tapentadol , alternative medicine , morphine , population , physical therapy , anesthesia , nursing , receptor , environmental health , pathology
The Indian Society for Study of Pain (ISSP), Cancer Pain Special Interest Group guidelines on pharmacological management of cancer pain in adults provides a structured, step-wise approach which will help to improve the management of cancer pain and to provide the patients with a minimally acceptable quality of life. The guidelines have been developed based on the available literature and evidence, to suit the needs, patient population, and situations in India. A questionnaire based on the key elements of each sub drafts addressing certain inconclusive areas where evidence was lacking, was made available on the ISSP website, and circulated by E-mail to all the ISSP and Indian Association of Palliative Care (IAPC) members. We recommend that analgesics for cancer pain management should follow the World Health Organization three-step analgesic ladder appropriate for the severity of pain. The use of paracetamol and nonsteroidal anti-inflammatory drugs alone or in combination with opioids for mild-to-moderate pain should be used. For mild-to-moderate pain, weak opioids such as tramadol, tapentadol, and codeine can be given in combination with nonopioid analgesics. We recommend morphine as the opioid of first choice for moderate-to-severe cancer pain.